Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
Alopecia areata (AA) is a non-scarring hair loss disorder. Alopecia totalis (AT) and alopecia universalis (AU) are the severe subtypes of AA. Age of onset before 6 years of age, disease duration of more than 1 year, and extensive alopecia involving more than 50% of the scalp (including AT or AU) sug...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1253795/full |
| _version_ | 1827796891740405760 |
|---|---|
| author | Lu Cai Lu Cai Yi Wei Min Zhao Jia Zhuo Xiao Tao Mao Lin Mao Lin |
| author_facet | Lu Cai Lu Cai Yi Wei Min Zhao Jia Zhuo Xiao Tao Mao Lin Mao Lin |
| author_sort | Lu Cai |
| collection | DOAJ |
| description | Alopecia areata (AA) is a non-scarring hair loss disorder. Alopecia totalis (AT) and alopecia universalis (AU) are the severe subtypes of AA. Age of onset before 6 years of age, disease duration of more than 1 year, and extensive alopecia involving more than 50% of the scalp (including AT or AU) suggest a poorer prognosis. Topical corticosteroids are the preferred first-line treatment for pediatric AA. While some treatments, such as intralesional corticosteroids, systemic steroids, contact immunotherapy with squaric acid dibutyl ester, and JAK inhibitors, showed efficacy in adults with AA, their safety profiles limit their use in pediatric AA patients. Dupilumab is a biologic that effectively addresses the patho-physiology of Th2 allergic diseases, and treats atopic diseases by inhibiting the helper Th2 immune axis. AA has been reported to be significantly improved with dupilumab for atopic dermatitis (AD) in children and adults. We report hair regrowth over all of the scalp, eyebrows, and eyelashes after 10 months of dupilumab therapy in a 4-year-old AU patient resistant to baricitinib. |
| first_indexed | 2024-03-11T19:12:30Z |
| format | Article |
| id | doaj.art-cb76c260be1c49bbb3ee8ebbc7380982 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-11T19:12:30Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-cb76c260be1c49bbb3ee8ebbc73809822023-10-09T10:35:03ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-10-011010.3389/fmed.2023.12537951253795Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinibLu Cai0Lu Cai1Yi Wei2Min Zhao3Jia Zhuo4Xiao Tao5Mao Lin6Mao Lin7Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, ChinaChongqing Medical University, Chongqing, ChinaDepartment of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, ChinaDepartment of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, ChinaDepartment of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, ChinaDepartment of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, ChinaDepartment of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, ChinaDepartment of Dermatology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaAlopecia areata (AA) is a non-scarring hair loss disorder. Alopecia totalis (AT) and alopecia universalis (AU) are the severe subtypes of AA. Age of onset before 6 years of age, disease duration of more than 1 year, and extensive alopecia involving more than 50% of the scalp (including AT or AU) suggest a poorer prognosis. Topical corticosteroids are the preferred first-line treatment for pediatric AA. While some treatments, such as intralesional corticosteroids, systemic steroids, contact immunotherapy with squaric acid dibutyl ester, and JAK inhibitors, showed efficacy in adults with AA, their safety profiles limit their use in pediatric AA patients. Dupilumab is a biologic that effectively addresses the patho-physiology of Th2 allergic diseases, and treats atopic diseases by inhibiting the helper Th2 immune axis. AA has been reported to be significantly improved with dupilumab for atopic dermatitis (AD) in children and adults. We report hair regrowth over all of the scalp, eyebrows, and eyelashes after 10 months of dupilumab therapy in a 4-year-old AU patient resistant to baricitinib.https://www.frontiersin.org/articles/10.3389/fmed.2023.1253795/fullalopecia areatadupilumabresistant to baricitinibpediatric patientsTh1Th2 |
| spellingShingle | Lu Cai Lu Cai Yi Wei Min Zhao Jia Zhuo Xiao Tao Mao Lin Mao Lin Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib Frontiers in Medicine alopecia areata dupilumab resistant to baricitinib pediatric patients Th1 Th2 |
| title | Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib |
| title_full | Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib |
| title_fullStr | Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib |
| title_full_unstemmed | Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib |
| title_short | Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib |
| title_sort | case report dupilumab therapy for alopecia areata in a 4 year old patient resistant to baricitinib |
| topic | alopecia areata dupilumab resistant to baricitinib pediatric patients Th1 Th2 |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1253795/full |
| work_keys_str_mv | AT lucai casereportdupilumabtherapyforalopeciaareataina4yearoldpatientresistanttobaricitinib AT lucai casereportdupilumabtherapyforalopeciaareataina4yearoldpatientresistanttobaricitinib AT yiwei casereportdupilumabtherapyforalopeciaareataina4yearoldpatientresistanttobaricitinib AT minzhao casereportdupilumabtherapyforalopeciaareataina4yearoldpatientresistanttobaricitinib AT jiazhuo casereportdupilumabtherapyforalopeciaareataina4yearoldpatientresistanttobaricitinib AT xiaotao casereportdupilumabtherapyforalopeciaareataina4yearoldpatientresistanttobaricitinib AT maolin casereportdupilumabtherapyforalopeciaareataina4yearoldpatientresistanttobaricitinib AT maolin casereportdupilumabtherapyforalopeciaareataina4yearoldpatientresistanttobaricitinib |